Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma

OBJECTIVE(S): To investigate the efficacy of pembrolizumab plus lenvatinib as a second-line or later-line therapy in women with advanced or recurrent uterine carcinosarcoma (UCS). METHODS: A single-institution pharmacy database was queried for women with advanced or recurrent UCS who were prescribed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Jonathan T., Chambers, Laura M., Yao, Meng, Joehlin-Price, Amy, Debernardo, Robert, Rose, Peter G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350419/
https://www.ncbi.nlm.nih.gov/pubmed/34401435
http://dx.doi.org/10.1016/j.gore.2021.100840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350419/
https://www.ncbi.nlm.nih.gov/pubmed/34401435
http://dx.doi.org/10.1016/j.gore.2021.100840

Ejemplares similares